Legal, Regulatory, and Business Intelligence Hub
With GLP-1 medications like semaglutide and tirzepatide now widely used for weight loss management, the legal, regulatory, and business challenges surrounding their use, particularly in 503A compounding, have become increasingly complex. Frier Levitt attorneys are at the forefront of this evolving landscape, providing critical insights for pharmacies, prescribers, and other stakeholders navigating this dynamic landscape.
This resource hub features our latest webinars and articles covering FDA guidance, reimbursement strategies, payer trends, state board enforcement, litigation risks, and compliance strategies to help you stay informed and compliant amid rapidly evolving developments in the GLP-1 space.
Featured Articles
- Lilly’s Retatrutide Lawsuits: A New Enforcement Playbook
– August 18, 2026
Eli Lilly and Company filed six federal lawsuits on August 12, 2026, against businesses it accuses of illegally selling retatrutide, the company’s experimental “triple-agonist” obesity drug that has not yet been approved by the U.S. FDA or any other regulator worldwide… - Arizona’s Withdrawn GLP-1 Compounding Bill Signals Increased Scrutiny – March 13, 2026
Arizona’s 2026 legislative session reflects a comprehensive effort to recalibrate the pharmacy regulatory landscape. In addition to sweeping PBM reform bills and amendments affecting the Arizona State Board of Pharmacy… - From Crackdown to Collaboration: FDA Warning Letters and the Hims-Novo Nordisk Deal Signal a New Era for Compounded GLP-1 Drugs – March 9, 2026
As federal regulators intensify scrutiny of compounded GLP-1 drugs and telehealth marketing practices, two developments in early March 2026 signal a turning point for the industry: a wave of FDA enforcement actions and a high-profile resolution between Hims & Hers Health and Novo Nordisk…
Featured Webinars
- The Fast and the Formulated: Navigating FDA Enforcement, GLP-1s, Peptides, and Emerging Business Models – August 20, 2026
Pharmacy compounding remains one of the most closely watched areas of FDA enforcement, particularly as compounded GLP-1s and peptides continue to draw regulatory and manufacturer attention… - Legal Insights into GLP-1 and Peptide Compounding in 2026 – March 18, 2026
As GLP-1 medications and peptide therapies continue to face heightened regulatory scrutiny, pharmacies and telehealth providers must navigate a rapidly shifting enforcement landscape… - Mastering GLP-1 Compounding Series Q&A Roundup – September 13, 2025
Frier Levitt’s healthcare and pharmacy law attorneys present a follow-up webinar tackling key issues based on the most pressing questions from our GLP-1 Compounding Series…
Meet Our Team
Edgar J. Asebey
Partner
973-852-8392
easebey@frierlevitt.com
Jesse C. Dresser
Partner
973-852-8361
jdresser@frierlevitt.com
Guilherme Ferrari Faviero
Senior Associate
332-205-6585
gferrari@frierlevitt.com
Arielle T. Miliambro
Partner
973-852-8379
amiliambro@frierlevitt.com
Brandon S. Zarsky
Partner
973-852-8398
bzarsky@frierlevitt.com
